NGNE earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -7.18. Updated 2026-07-23.
Neurogene (NGNE) Research Hub
Neurogene (NGNE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 35.48 USD (-6.34%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.18, market cap 0.57B. This hub links to the full technical, earnings and options research available for NGNE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 35.48 USD (-6.34%) |
| 52-week range | 28.91 USD – 43.66 USD |
| Trend regime | Range |
| 14-day RSI | 49.4 (Neutral) |
| Trailing P/E | -7.18 |
| Market cap | 0.57B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for NGNE
Covered Call on NGNE: how it works, illustrative setup around the real 35.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NGNE: how it works, illustrative setup around the real 35.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NGNE: how it works, illustrative setup around the real 35.48 USD price, max profit/loss, breakeven and when to use it. Educational.
NGNE technical analysis: range, last 35.48 USD, RSI 49.4, 52w range 28.91 USD–43.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NGNE in?
Neurogene (NGNE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NGNE in an uptrend or downtrend?
As of 2026-09-11, NGNE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NGNE's trailing P/E ratio?
NGNE's trailing P/E is -7.18, with a market cap of 0.57B. See the earnings research page for full valuation detail.
When does NGNE next report earnings?
NGNE is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -1.4 USD.